Covid-19 update: Nawab Malik ने Modi government पर लगाया निशाना , India में Moderna कैसे हो रही इस्तेमाल

Publish Date: 14 May, 2021 |
 

Covid-19 update:

The cases of the covid-19 virus are again on surge in Maharashtra after dipping in numbers for two days, while the overall fresh cases of coronavirus across the country have dipped within the past few days. 

And recently, the Maharashtra minister and nationalist Congress Party (NCP) Chief Nawab Malik targetted the Central government and asked about the Moderna (non-permitted) vaccine being administered to the residents of France and their relatives residing in India. 

Malik in a tweet asking for clarity on the matter quoted, “Covishield, Covaxina and, Sputnik V are the three vaccines that are permitted in India by our government. According to information received by me, the French Embassy in India has produced the vaccine @moderna_tx and is inoculating their citizens and their relatives at Navi Mumbai with the help of @ApolloHosMumbai. Question arises, how can a non-permitted vaccine be allowed to be administered? If they can get it, why can’t the Indian government get it for our citizens too? The government and the Health minister @drharshvardhan must clarify.”

While in return to it, the BJP legislator Ram Kadam quoted, “It is the right of every embassy to give whatever vaccine they want to their employees. The state has the Food and Drug Administration (FDA) which should take action if they want. They just want to divert the topic.” 

It must be noted that the state government is accusing the Central government for the vaccine crisis in the country stating that it is the centre that allots the vaccines to states, and for any shortage, they should be held accountable. Moreover, the state ministers said that the central government didn’t alloted sufficient vaccines to Maharastra and played a biased game. 


 

यह भी पढ़ें

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy.Accept